Alx Oncology Holdings (ALXO) Share-based Compensation (2019 - 2026)

Alx Oncology Holdings' Share-based Compensation history runs 8 years deep, the most recent figure standing at $2.5 million for Q1 2026.

• In Q1 2026, Share-based Compensation fell 51.9% year-over-year to $2.5 million; the TTM figure through Mar 2026 stood at $9.9 million (down 60.95% YoY), while the FY2025 annual figure was $12.6 million, down 53.57% from the prior year.
• Share-based Compensation came in at $2.5 million for Q1 2026 at Alx Oncology Holdings, down from $2.7 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $7.3 million in Q2 2024 to a low of $2.1 million in Q2 2025.
• A 5-year average of $5.4 million and a median of $6.2 million in 2022 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation jumped 205.61% in 2022 and slumped 70.55% in 2025, its largest moves.
• Alx Oncology Holdings' Share-based Compensation stood at $6.3 million in 2022, then gained by 6.77% to $6.7 million in 2023, then retreated by 12.84% to $5.9 million in 2024, then sank by 53.81% to $2.7 million in 2025, then declined by 7.28% to $2.5 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $2.5 million, $2.7 million, and $2.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison